贾贺;李惠勉;

• 1:郑州大学第二附属医院

摘要(Abstract)：

目的研究2型糖尿病大鼠行为及认知功能的改变及吡哆胺干预的影响。方法建立2型糖尿病大鼠模型,吡哆胺灌胃干预,通过行为学检测及Morris水迷宫试验观察大鼠行为及认知功能的变化。结果与对照组相比,模型组及干预组大鼠卒中指数显著增高(P<0.05),潜伏期明显延长,穿越平台位置次数明显减少(P<0.05);与模型组相比,干预组大鼠卒中指数显著降低,潜伏期显著缩短、穿越平台位置次数明显增加(P<0.05)。结论 2型糖尿病可造成大鼠不同程度的行为及认知功能障碍,吡哆胺干预可改善2型糖尿病大鼠神经功能。

关键词(KeyWords)： 吡哆胺;糖尿病;行为功能;认知功能;大鼠

Abstract:

Keywords:

基金项目(Foundation): 河南省科技厅科技攻关项目(编号：122102310623)

作者(Authors): 贾贺;李惠勉;

参考文献(References)：

• [1] LIU S L.Research advances in cognitive impairment induced by type 2diabetes[J].J Chongqing Med Univ,2019,44(4):404-410.
• [2] MAZZONE T,CHAIT A,PLUTZKY J.Cardiovascular disease risk in type 2diabetes mellitus:insights from mechanistic studies[J].Lancet(London,England),2008,371(9 626):1800-1809.
• [3] MANSCHOT S M,BRANDS A M,VAN DER GROND J,et al.Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2diabetes[J].Diabetes,2006,55(4):1106-1113.
• [4] STEWART R,LIOLITSA D.Type 2diabetes mellitus,cognitive impairment and dementia[J].Diabetic Med,1999,16(2):93-112.
• [5] GAO H L,LI H W.Research progress on the relationship between metabolites and their receptors at the end of glycosylation and atherosclerosis inhibitors[J].J Clin Expe Med,2016,15(6):610-613.
• [6] WILLIAMS M E.New potential agents in treating diabetic kidney disease:the fourth act[J].Drugs,2006,66(18):2287-2298.
• [7] HUANG Y,ZHENG W D.Effect of Pyridoxamine on Advanced Glycation end Products and their Receptors in the Retina of Diabetic Rats[J].J Fujian Med Univ,2012,46(1):11-14.
• [8] HUANG Y.Effect of Pyridoxamine on AGE and RAGE expression in the visual cortex in diabetic rats[J].Chin J Histochem Cytochem,2014,23(1):55-59.
• [9] HE J.Effects of aminoguanidine on behavioral changes and Spinophilin Expression in type 2diabetes rats[J].Chin J Gerontol,2017,37(12):2870-2872.
• [10] SHI H,JIN G Q.Establishing methods for constructing rat models of type 2diabetes mellitus which are the most similar to human beings[J].Chin J Rehabil,2005,3(39):69-71.
• [11] YAHG Y,YOU H Y.Comparison of the Three Models on Blood Glucose Fluctuation of Diabetic Rats[J].J Kunming Med Univ,2017,38(12):12-17.
• [12] NI J,OHTA H,MATSUMOTO K,et al.Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats[J].Brain Res,1994,653(1):231-236．
• [13] JIA H,ZHANG B.Changes of dendritic morphology and spine density in hippocampal CA1pyramidal cells of chronic cerebral ischemic rats[J].Chin J Pathophysiol,2012,28(1):177-180.
• [14] GROSSMAN S D,FUTTER M,SNYDER G L,et al.Spinophilin is phosphorylated byCa2+/calmodulin-dependent protein kinase II resulting in regulation ofits binding to F-actin[J].J Neurochem,2004,90(2):317-324．
• [15] PUTAALA J,LIEBKIND R,GORDIN D,et al.Diabetes mellitus and ischemic stroke in the young:clinical features and long-term prognosis[J].Neurology,2011,76:1831-1837.
• [16] Collaboration TERF.Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102prospective studies[J].Lancet,2010,375:2215-2222.
• [17] BIESSELS G J.Cerebral complications of diabetes:clinical findings and pathogenetic mechanisms[J].Neth J Med,1999,54(2):35-45.
• [18] DEN HEIJER T,VERMEER S E,VAN DIJK E J,et al.Type 2diabetes and atrophy of medial temporal lobe structures on brain MRI[J].Diabetologia,2003,46(12):1604-1610.
• [19] DATTA S R,DUDEK H,TAO X,et al.Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery[J].Cell,1997,91(2):231-241．
• [20] ERGUL A,ABDELSAID M,FOUDA A Y,et al.Cerebral neovascularization in diabetes:implications for stroke recovery and beyond[J].J Cereb Blood Flow Metab,2014,34(4):553-563.
• [21] PRAKASH R,SOMANATH P R,EL-REMESSY A B,et al.Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2diabetes involves VEGF and peroxynitrite signaling[J].Diabetes,2012,61:1533-1542.
• [22] PRAKASH R,JOHNSON M,FAGAN S C,et al.Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes[J].PLoS One,2013,8:e56264.
• [23] CHEN J L,FRANCIS J.Pyridoxamine,advanced glycation inhibition,and diabetic nephropathy[J].J Am Soc Nephrol,2012,23(1):3-12.
• [24] ZHENG Z K.Effect of pyridoxamine on advanced glycosylation end-products and their receptors in arteriosclerotic rabbits[J].Chin J Cerebrovasc Dis,2016,13(11):588-592;600.
• [25] ZHAO Y L,YU T.Inhibitory effects of pyridoxamine on advanced glycation and advanced glycation end products formation in vitro[J].Chin J Lab Diagn,2005,9:783-785．
• [26] ZHENG F,ZENG Y J,PLATI A R,et al.Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6db/db mice[J].Kidney Int,2006,70(3):507-514.
• [27] PAUL G,ZACHRISSON O,VARRONE A,et al.Safety and tolerability of intracerebroventricular PDGFBB in Parkinson's disease patients[J].J Clin Invest,2015,125(3):1339-1346.
• [28] WILLIAMS M E.New potential agents in treating diabetic kidney disease:the fourth act[J].Drugs,2006,66(18):2287-2298.